L Wideroff

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions
    L Wideroff
    NCI ARB, EPN 313 MSC 7344, Bethesda, MD 20892 7344, USA
    J Infect Dis 180:1424-8. 1999
  2. ncbi A health services research agenda for cellular, molecular and genomic technologies in cancer care
    Louise Wideroff
    National Cancer Institute, Bethesda, MD, USA
    Public Health Genomics 12:233-44. 2009
  3. ncbi Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians
    L Wideroff
    Applied Research Program Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
    J Med Genet 42:749-55. 2005
  4. ncbi Awareness of genetic testing for increased cancer risk in the year 2000 National Health Interview Survey
    Louise Wideroff
    National Cancer Institute, Division of Cancer Control and Population Sciences, National Institutes of Health, Bethesda, MD 20892 7344, USA
    Community Genet 6:147-56. 2003
  5. ncbi Coherence and completeness of population-based family cancer reports
    Louise Wideroff
    National Cancer Institute, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 19:799-810. 2010
  6. ncbi Physician use of genetic testing for cancer susceptibility: results of a national survey
    Louise Wideroff
    National Cancer Institute, Division of Cancer Control and Population Sciences, Bethesda, Maryland 20892 7344, USA
    Cancer Epidemiol Biomarkers Prev 12:295-303. 2003
  7. ncbi GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas
    Louise Wideroff
    Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, EPN 4005, 6130 Executive Boulevard, MSC 7344, Bethesda, MD 20892 7344, USA
    Cancer Detect Prev 31:233-6. 2007
  8. ncbi US physicians' attitudes toward genetic testing for cancer susceptibility
    A N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute NIH, EPN 4005 MSC 7344, 6130 Executive Boulevard, Bethesda, MD 20892 7344, USA
    Am J Med Genet A 120:63-71. 2003
  9. ncbi Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study
    P L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    Public Health Genomics 13:495-503. 2010
  10. ncbi Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007
    K Robin Yabroff
    National Cancer Institute and the National Institutes of Health, Bethesda, and Information Management Services, Silver Spring, Maryland, USA
    Ann Intern Med 151:602-11. 2009

Detail Information

Publications19

  1. ncbi Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions
    L Wideroff
    NCI ARB, EPN 313 MSC 7344, Bethesda, MD 20892 7344, USA
    J Infect Dis 180:1424-8. 1999
    ..These data suggest that seroreactivity to a given type reflects mainly type-specific HPV infection as measured by DNA detection and may also signal past exposure to other types that are now only serologically detected...
  2. ncbi A health services research agenda for cellular, molecular and genomic technologies in cancer care
    Louise Wideroff
    National Cancer Institute, Bethesda, MD, USA
    Public Health Genomics 12:233-44. 2009
    ..In recent decades, extensive resources have been invested to develop cellular, molecular and genomic technologies with clinical applications that span the continuum of cancer care...
  3. ncbi Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians
    L Wideroff
    Applied Research Program Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
    J Med Genet 42:749-55. 2005
    ....
  4. ncbi Awareness of genetic testing for increased cancer risk in the year 2000 National Health Interview Survey
    Louise Wideroff
    National Cancer Institute, Division of Cancer Control and Population Sciences, National Institutes of Health, Bethesda, MD 20892 7344, USA
    Community Genet 6:147-56. 2003
    ..This study explores factors associated with differential awareness of genetic tests for increased cancer risk in the US...
  5. ncbi Coherence and completeness of population-based family cancer reports
    Louise Wideroff
    National Cancer Institute, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 19:799-810. 2010
    ..Given its widespread use in cancer screening and surveillance, better information is needed about the clarity and accuracy of family history information reported in the general population...
  6. ncbi Physician use of genetic testing for cancer susceptibility: results of a national survey
    Louise Wideroff
    National Cancer Institute, Division of Cancer Control and Population Sciences, Bethesda, Maryland 20892 7344, USA
    Cancer Epidemiol Biomarkers Prev 12:295-303. 2003
    ..39; 95% CI, 0.23-0.66%). These findings underscore the importance of establishing effective clinical approaches to test use and promoting physician education to facilitate communication with patients about cancer genetics...
  7. ncbi GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas
    Louise Wideroff
    Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, EPN 4005, 6130 Executive Boulevard, MSC 7344, Bethesda, MD 20892 7344, USA
    Cancer Detect Prev 31:233-6. 2007
    ..In a population-based case-control study, we examined risks in relation to polymorphisms of the following genes: GSTP1; GSTM1; GSTT1; NAT1; and CYP1A1...
  8. ncbi US physicians' attitudes toward genetic testing for cancer susceptibility
    A N Freedman
    Division of Cancer Control and Population Sciences, National Cancer Institute NIH, EPN 4005 MSC 7344, 6130 Executive Boulevard, Bethesda, MD 20892 7344, USA
    Am J Med Genet A 120:63-71. 2003
    ..Results of this national survey underscore the need to provide physicians with clear guidelines on the use of genetic cancer susceptibility tests and effective medical training on their appropriate implementation...
  9. ncbi Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study
    P L Mai
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    Public Health Genomics 13:495-503. 2010
    ..A positive family history is a known risk factor for several cancers; thus, obtaining a thorough family cancer history is essential in cancer risk evaluation and prevention management...
  10. ncbi Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007
    K Robin Yabroff
    National Cancer Institute and the National Institutes of Health, Bethesda, and Information Management Services, Silver Spring, Maryland, USA
    Ann Intern Med 151:602-11. 2009
    ..Little information is available about primary care physicians' current Papanicolaou (Pap) test screening practices, including initiation, frequency, and stopping...
  11. ncbi U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality
    Marie Josèphe Horner
    Laboratory for Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 20:591-9. 2011
    ..To define priority areas for prevention efforts, we examined the geographic distribution of cervical cancer screening, incidence, stage, and mortality in the United States, prior to the introduction of HPV-based prevention technologies...
  12. ncbi Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites
    Karen Woodson
    Cancer Prevention Studies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Prostate 55:199-205. 2003
    ..Epigenetic events such as promoter-region gene hypermethylation may be influenced by environmental exposures and have been implicated in prostate carcinogenesis (by the silencing of tumor suppressors and other regulatory genes)...
  13. ncbi Population estimates of extended family structure and size
    Anne Garceau
    Division of Cancer Control and Population Sciences, Risk Factor Monitoring and Methods Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Community Genet 11:331-42. 2008
    ..Population-based estimates of biological family size can be useful for planning genetic studies, assessing how distributions of relatives affect disease associations with family history and estimating prevalence of potential family support...
  14. ncbi Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility
    Susan Thomas Vadaparampil
    Health Outcomes and Behavior Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Am J Med Genet A 135:41-6. 2005
    ..At that time, one-quarter of the physicians considered advertisements to play an important role in their clinical decision making, suggesting attention to other sources of information and additional factors...
  15. ncbi The impact of acculturation on awareness of genetic testing for increased cancer risk among Hispanics in the year 2000 National Health Interview Survey
    Susan T Vadaparampil
    Health Outcomes and Behavior Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, USA
    Cancer Epidemiol Biomarkers Prev 15:618-23. 2006
    ..These factors must be taken into account when informing individuals about the role of genetics in cancer risk and providing cancer genetic health services...
  16. ncbi Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study
    Gustaf Edgren
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Lancet 369:1724-30. 2007
    ..Our aim was to investigate the possible risk of cancer transmission from blood donors to recipients through blood transfusion...
  17. ncbi Cancer incidence in blood transfusion recipients
    Henrik Hjalgrim
    Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, DK 2300 Copenhagen South, Denmark
    J Natl Cancer Inst 99:1864-74. 2007
    ..Blood transfusions may influence the recipients' cancer risks both through transmission of biologic agents and by modulation of the immune system. However, cancer occurrence in transfusion recipients remains poorly characterized...
  18. ncbi Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study
    Cynthia Bierl
    Viral Exanthems and Herpesvirus Branch, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Gynecol Oncol 99:S262-8. 2005
    ..In addition, standardization of mucosal sample collection and testing methods are required...
  19. ncbi Genetic test evaluation: information needs of clinicians, policy makers, and the public
    Wylie Burke
    University of Washington, Seattle, WA, USA
    Am J Epidemiol 156:311-8. 2002
    ....